➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKesson
Johnson and Johnson
Colorcon
Baxter

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,722,700

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,722,700 protect, and when does it expire?

Patent 8,722,700 protects TORISEL and is included in one NDA.

Protection for TORISEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: 8,722,700
Title:CCI-779 formulations for parenteral administration
Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
Inventor(s): Rubino; Joseph T. (Towaco, NJ), Siskavich; Victoria (Lyon Mountain, NY), Harrison; Maureen M. (Sugar Loaf, NY), Gandhi; Pooja (Highland Mills, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:13/892,389
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 8,722,700

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Mallinckrodt
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.